Accessibility Menu
Basilea Pharmaceutica Ag logo

Basilea Pharmaceutica Ag

(OTC) BPMUF

Current Price$60.28
Market Cap$747.28M
Since IPO (2004)+19%
5 Year+31%
1 Year+4%
1 Month-13%

Basilea Pharmaceutica Ag Financials at a Glance

Market Cap

$747.28M

Revenue (TTM)

CHF 441.00M

Net Income (TTM)

CHF 117.80M

EPS (TTM)

$3.67

P/E Ratio

15.13

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$60.28

Volume

12

Open

$60.28

Previous Close

$60.28

Daily Range

$60.28 - $60.28

52-Week Range

$57.70 - $74.00

Estimated Earnings Date

Aug 18, 2026

BPMUF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Basilea Pharmaceutica Ag

Industry

Biotechnology

Employees

189

CEO

David Veitch

Headquarters

Allschwil, 4058, CH

BPMUF Financials

Key Financial Metrics (TTM)

Gross Margin

74%

Operating Margin

22%

Net Income Margin

18%

Return on Equity

39%

Return on Capital

17%

Return on Assets

11%

Earnings Yield

6.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$747.28M

Shares Outstanding

12.40M

Volume

12

Avg. Volume

0.906

Financials (TTM)

Gross Profit

CHF 193.19M

Operating Income

CHF 51.62M

EBITDA

CHF 51.05M

Operating Cash Flow

CHF 62.12M

Capital Expenditure

-CHF 2.62M

Free Cash Flow

CHF 59.50M

Cash & ST Invst.

CHF 162.41M

Total Debt

CHF 89.22M

Basilea Pharmaceutica Ag Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CHF 128.50M

+76.7%

Gross Profit

CHF 113.42M

+102.8%

Gross Margin

88.27%

N/A

Market Cap

$747.28M

N/A

Market Cap/Employee

$4.56M

N/A

Employees

164

N/A

Net Income

CHF 24.41M

+214.1%

EBITDA

CHF 29.37M

+833.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CHF 162.41M

+171.1%

Total Debt

CHF 89.22M

-30.6%

Accounts Receivable

CHF 63.31M

+127.0%

Inventory

CHF 21.57M

-18.3%

Long Term Debt

CHF 87.16M

-21.5%

Short Term Debt

CHF 2.06M

-88.2%

Return on Assets

11.45%

N/A

Return on Invested Capital

17.00%

N/A

Free Cash Flow

CHF 36.75M

+544.7%

Operating Cash Flow

CHF 39.05M

+612.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOLTFNxera Pharma Co., Ltd.
$6.19+0.00%
INRLFValneva SE
$2.58+0.00%
PTCHFPureTech Health plc
$1.70+0.00%
VBIZFViva Biotech Holdings
$0.13+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$185.00-0.04%
NOKNokia
$13.49-0.02%
AALAmerican Airlines Group
$15.99+0.04%
TAT&T
$22.01-0.02%

Questions About BPMUF

What is the current price of Basilea Pharmaceutica Ag?

Basilea Pharmaceutica Ag is trading at $60.28 per share.

What is the 52-week range for Basilea Pharmaceutica Ag?

Over the past 52 weeks, Basilea Pharmaceutica Ag has traded between $57.70 and $74.00.

How much debt does Basilea Pharmaceutica Ag have?

As of the most recent reporting period, Basilea Pharmaceutica Ag reported total debt of CHF 112.61M.

How much cash does Basilea Pharmaceutica Ag have on hand?

Basilea Pharmaceutica Ag reported CHF 37.41M in cash and cash equivalents in its most recent financial results.

What is Basilea Pharmaceutica Ag’s dividend yield?

Basilea Pharmaceutica Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.